{"entity":{"id":"nct05491525","kind":"trial","name":"Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC","aka":[],"tldr":"A phase 2/3 trial of Vibegron in childhood cancers, run by Urovant Sciences GmbH, now recruiting.","summary":"Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC is a phase 2/3 interventional study registered as NCT05491525 by Urovant Sciences GmbH, with 71 participants planned, started 2022-10-12 and due to reach its primary completion in 2030-03. Interventions recorded: Vibegron.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05491525","url":"https://clinicaltrials.gov/study/NCT05491525"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["childhood-cancers"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05491525","phase":"2/3","setting":"A Phase 2/3, Open-label, Baseline-controlled, Multicenter, Long-term Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC)","sponsor":"Urovant Sciences GmbH","enrolled":71,"outcomes":[]},"route":"/trials/nct05491525/","neighbours":{"cancer":[{"id":"childhood-cancers","kind":"cancer","name":"Childhood cancers (all types)","route":"/cancers/childhood-cancers/"}]}}